We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Rapid Test Detects Both HIV and TB in Blood Sample

By LabMedica International staff writers
Posted on 21 Nov 2023

HIV and tuberculosis (TB) frequently occur together, posing a significant health challenge. More...

HIV weakens the immune system, increasing susceptibility to infections like TB. Indeed, individuals with HIV are at the greatest risk of developing TB. Traditional TB diagnosis involves culturing sputum, saliva, and mucus mix, but this process is time-consuming and often not feasible for urgent treatment needs. Additionally, sputum collection is not viable for HIV patients due to their compromised immune systems. To fill this diagnostic gap, researchers have developed a rapid, dual-detection blood test that can identify both HIV and TB simultaneously using just a small blood sample.

This breakthrough blood test, developed by researchers at Tulane University (New Orleans, LA, USA), not only identifies HIV and TB but also measures their respective viral and bacterial loads. Requiring only about 200 microliters of blood – a mere few drops – the test bypasses the need for sputum samples, making it particularly useful for HIV patients. It operates by targeting specific HIV and TB antigens present in the blood, utilizing mass spectrometry for precise measurement of viral and bacterial quantities.

A key benefit of this novel test is its ability to monitor the levels of both HIV and TB during a patient's treatment. This real-time tracking is crucial in managing immune reconstitution inflammatory syndrome (IRIS), a condition where treating one infection may exacerbate the other. The test's rapid results allow for timely adjustments in treatment strategies, enhancing patient outcomes. Such tests are especially critical in developing countries, where TB is more prevalent and access to diagnostic resources is limited. The researchers are optimistic about progressing from their initial pilot study to clinical trials and are aiming for FDA approval of the test.

“For HIV patients, their immune system is very weak, and once they are infected, they can’t confront the bacteria very well, so that’s why there is this urgent need to bring a blood-based TB tests to them,” said Tony Hu at Tulane University School of Medicine who led the research. “For the TB-infected patients, they worry, ‘Why did I get TB? Is it because I have HIV?’ So, this is a multiplex detection to cover both pathogens.”

Related Links:
Tulane University


Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.